Non-opioid Pain Focus Target customers in both human and companion animal health markets seeking non-opioid analgesics, highlighting EicOsis' development of non-narcotic pain treatments and FDA Fast Track recognition to accelerate adoption.

Early Stage Funding Opportunity to engage with EicOsis during and after SBIR/NCI funding cycles and Open Philanthropy investment phases, positioning clinical development services, regulatory consulting, or partnering for trial support.

UC Davis Origins Leverage proximity to UC Davis research lineage and Professor Bruce Hammock’s work to propose collaborative R&D, tech transfer, or joint development programs that align with university-affiliated innovation funding and partnerships.

Strategic Partnerships Position as a potential collaborator for translational research, CRO/CMC services, and clinical trial support to move EC5026 and related candidates toward human trials, leveraging the company’s SBIR trajectory and growth ambitions.

Growing Yet Lean With a small team and modest revenue scale, offer scalable, cost-effective solutions such as outsourced development, regulatory filings, and pilot manufacturing to support rapid progression through clinical milestones.